CDK16 and ovarian carcinoma: Duan et al. [18] provided a piece of evidence that hsa-miR-494 might be a vital regulator in promoting the advancement of nasopharyngeal carcinoma by inhibiting polypeptide N-acetylgalactosaminyltransferase 7 (GALNT7) and cyclin-dependent kinase 16 (CDK16), while hsa-miR-494 has a tumor-suppressing force in ovary carcinoma via suppressing cell migration and growth and promoting cell apoptosis [19, 20].